Edaravone

Evidence Level: L5 Predicted Indications: 2

Table of Contents

  1. Edaravone
    1. Pharmacist Assessment Report
    2. Edaravone: From Ischemic Stroke and ALS to Heparin Cofactor 2 Deficiency
    3. One-Sentence Summary
    4. Quick Overview
    5. Why is This Prediction Reasonable?
    6. Clinical Trial Evidence
    7. Literature Evidence
    8. India Market Information
    9. Safety Considerations
    10. Conclusion and Next Steps
    11. Disclaimer

Pharmacist Assessment Report

Edaravone: From Ischemic Stroke and ALS to Heparin Cofactor 2 Deficiency

One-Sentence Summary

Edaravone is a free radical scavenger originally used to treat ischemic stroke and amyotrophic lateral sclerosis (ALS). The TxGNN model predicts it may be effective for heparin cofactor 2 deficiency, but this rests on a model prediction only, with 0 clinical trials and 0 publications supporting it.

Quick Overview

Item Content
Original Indication Ischemic stroke, stroke disorder, amyotrophic lateral sclerosis (approved indication text is not available in the India registrations)
Predicted New Indication Heparin cofactor 2 deficiency
TxGNN Prediction Score 0.9947
Evidence Level L5
India Market Status Listed in a compiled Indian medicine price dataset (at least 20) – CDSCO approval status is not included in this data
Number of Listed Products at least 20
Recommended Decision Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available. Based on known information, edaravone is a free radical scavenger with established use in ischemic stroke and ALS. A speculative link is that it may reduce oxidative endothelial injury, which could in theory lower thrombotic risk in a prothrombotic condition.

This link is weak. Heparin cofactor 2 deficiency is a defect in dermatan sulfate-dependent thrombin inhibition, and a radical scavenger would not correct it. The prediction is therefore hypothetical and unvalidated.

A second prediction, factor 5 excess with spontaneous thrombosis (score 0.9906), has the same limitations. Edaravone does not target the coagulation cascade, and no trials or publications support it.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

India Market Information

Edaravone has 20 valid single-ingredient registrations in India and none are cancelled. The registrations include no approved indication text. Five of them are listed below.

Authorization Number Product Name Dosage Form Approved Indication
Registration No. 77525 Edivone 1.5mg Injection Vial of 20 ml injection Not stated
Registration No. 72868 Edastar Injection Vial of 20 ml injection Not stated
Registration No. 74902 Edastar 1.5mg Tablet Strip of 10 tablets Not stated
Registration No. 88647 Fraseda 1.5mg Injection Vial of 20 ml injection Not stated
Registration No. 494 Aravon Injection Vial of 20 ml injection Not stated

Most products are injectables, and one oral tablet is registered.

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Hold

Rationale: The prediction rests on a model score alone, with no clinical trials or literature. The proposed mechanism does not fit the underlying defect in thrombin inhibition, so there is no basis to advance it.

To proceed, the following is needed:

  • Mechanism of action data to assess any biological link to the predicted conditions
  • Package insert warnings and contraindications for the India-registered products
  • Preclinical or mechanistic studies showing edaravone affects thrombin inhibition or coagulation
  • Route compatibility assessment and similarity analysis against the original indications

    Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.